Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Background Evidence from retrospective studies suggests that disease progression after first-
line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …

Importance Patterns-of-failure studies suggest that in metastatic non–small-cell lung cancer
(NSCLC) sites of gross disease at presentation are the first to progress when treated with …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

Objective To determine the availability of data on overall survival and quality of life benefits
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …